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Abstract
Introduction The role of circulating tumor cells (CTCs) in blood
of primary breast cancer patients is still under investigation. We
evaluated the incidence of CTCs in blood, we evaluated the
correlation between CTCs and disseminated tumor cells
(DTCs) in the bone marrow (BM), and we characterized CTCs
for the expression of HER2, the estrogen receptor (ER) and the
progesterone receptor (PR).
Methods Blood of 431 patients with primary breast cancer
were analyzed for EpCAM, MUC1 and HER2 transcripts with
the  AdnaTest BreastCancer™ (AdnaGen AG, Germany).
Expression of the ER and PR was assessed in an additional RT-
PCR. BM aspirates from 414 patients were analyzed for DTCs
by immunocytochemistry using the pan-cytokeratin antibody
A45-B/B3.
Results DTCs were found in 107/414 patients (24%), CTCs
were detected in 58/431 (13%) patients. DTCs were
associated with PR status of the primary tumor (P = 0.04) and
CTCs significantly correlated with nodal status (P = 0.04), ER
(P  = 0.05), and PR (P  = 0.01). DTCs in the BM weakly
correlated with CTCs (P  = 0.05) in blood. Interestingly, the
spread of CTCs was mostly found in triple-negative tumors (P =
0.01) and CTCs in general were mostly found to be triple-
negative regardless of the ER, PR and HER2 status of the
primary tumor.
Conclusions (1) Due to the weak concordance between CTCs
and DTCs the clinical relevance may be different. (2) The biology
of the primary tumor seems to direct the spread of CTCs. (3)
Since the expression profile between CTCs and the primary
tumor differs, the consequence for the selection of adjuvant
treatment has to be evaluated.
Introduction
Disseminated tumor cells (DTCs) in the bone marrow (BM) are
a common phenomenon seen in breast cancer at primary diag-
nosis in up to 40% of patients [1-3]. Tumor cell detection in
the BM is regarded increasingly as a clinically relevant prog-
nostic factor for breast cancer, and a pooled analysis of BM
findings in more than 4,700 patients documented that their
presence is associated with a poor prognosis [4]. In addition,
it has been demonstrated that tumor cells frequently survive
chemotherapy [5] and the persistence of these cells in BM
after conventional adjuvant chemotherapy is associated with
poor prognosis [6-8]. The consequences for a possible sec-
ondary adjuvant therapy are under discussion. Since BM aspi-
ration is less accepted by patients compared with blood
drawing, it would be highly desirable to replace BM aspiration
by blood analysis.
For the detection of circulating tumor cells (CTCs) in blood,
both antibody-based assays using antibodies against epithe-
lial specific markers (for example, cytokeratins (CKs)) and
molecular assays (for example, based on amplification of
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epithelial-specific mRNA transcripts) have been established
[9-20].
The most currently used approach, particularly in clinical trials,
is the CellSearch™ System (Veridex, Warren, NJ, USA), which
is as a semi-automated device based on immunofluorescence
and flow cytometry. CTCs are isolated by immunomagnetic
beads coated with antibodies against the epithelial cell adhe-
sion molecule (EpCAM) and are identified by CK positivity,
positive nuclear staining and CD45 negativity [9,10,18].
Another commercially available CTC detection system is the
AdnaTest BreastCancer™ (AdnaGen AG, Langenhagen, Ger-
many). First, CTCs are isolated by immunomagnetic beads
labeled with antibodies against MUC1 and EpCAM. After iso-
lation of the mRNA, transcripts of epithelial-specific markers
(GA 73.3, EpCAM and human epidermal growth factor recep-
tor 2 (HER2)) are amplified by a multiplex PCR [21-23].
Based on current data, the concordance rate of the Cell-
Search™ assay and the AdnaTest BreastCancer™ ranges
between 68% and 88% [24,25]. A prospective multicenter
trial in metastatic breast cancer using both methods – the
CellSearch™ assay and the AdnaTest BreastCancer™ – to re-
evaluate the HER2 status by circulating CTC has recently
completed its recruitment, but the data on concordance have
not yet been published [26].
The clinical significance of CTCs in metastatic breast cancer
has been clearly demonstrated [9,10]. In contrast, the predic-
tive and prognostic value of CTCs in primary breast cancer is
still under investigation [11-17]. Single-center studies have
indicated that the presence of CTCs at the time of first diag-
nosis is an independent prognostic factor for overall and dis-
ease-free survival [11-13,27,28]. In addition, patients with
CTC persistence after completion of systemic cytotoxic ther-
apy are more likely to develop relapse compared with those
who were CTC-negative [29,30]. Targeting persistent CTCs
is therefore an important issue to improve prognosis in primary
breast cancer patients.
In this context, the need to determine the expression of thera-
peutic relevant markers in minimal residual disease is becom-
ing increasingly important to optimize adjuvant treatment.
Adjuvant therapy targets minimal residual disease, which is
reflected by CTCs and DTCs. It has already been shown that
the expression of therapeutic relevant markers including estro-
gen receptor (ER) and HER2 may differ from that of the pri-
mary tumor [31,32]. These observed discrepancies may be
the cause of tumor cell persistence and therapeutic failure in
the adjuvant setting.
In the present study we have used a RT-PCR-based approach
to examine the presence of CTCs in peripheral blood of
patients with primary breast cancer, to assess the correlation
between CTCs in blood and DTCs in BM, and to compare the
expression profile of therapeutic relevant markers (HER2, ER,
progesterone receptor (PR)) between CTCs and the primary
tumor.
Materials and methods
Patients' characteristics
The study was conducted at the Department of Obstetrics and
Gynecology in Essen and in the Department of Obstetrics and
Gynecology in Tübingen. In total, 431 primary breast cancer
patients (pT1 to pT4, pN0 to PN2, Mo) have been studied.
Patients' characteristics at the time of diagnosis are presented
in Table 1.
Collection and analysis of bone marrow
Between 10 and 20 ml BM were aspirated from the anterior
iliac crests of 414 out of 431 primary breast cancer patients
at the time of surgery and were processed within 24 hours. All
specimens were obtained after written informed consent and
were collected using protocols approved by the institutional
review board (Protocol 114/2006A and Protocol 05/2856).
Tumor cell isolation and detection was performed based on
the recommendations for standardized tumor cell detection
recently published by the German Consensus Group of Senol-
ogy [33].
BM cells were isolated from heparinized BM (5,000 U/ml BM)
by Ficoll-Hypaque density gradient centrifugation (density
1.077 g/mol; Pharmacia, Freiburg, Germany) at 400 × g for 30
minutes. Interface cells were washed (400 × g for 15 min) and
resuspended in PBS. Then 1 × 106mononuclear cells per area
of 240 mm2 from each aspiration side were directly spun onto
glass slides (400 × g  for 5 min) coated with poly-l-lysine
(Sigma, Deisenhofen, Germany) using a Hettich cytocentri-
fuge (Tuttlingen, Germany) for the detection of CK-positive
cells. The slides were air-dried overnight at room temperature.
Immunocytochemistry
Staining for CK-positive cells was performed using the murine
mAb A45-B/B3 (Micromet, Munich, Germany), directed
against a common epitope of CK polypeptides including the
CK heterodimers 8/18 and 8/19 [13,27,28,32]. The protocol
has been described in detail elsewhere [34]. Briefly, the
method includes permeabilization of the cells with a detergent
(5 min), fixation with a formaldehyde-based solution (10 min),
binding of the conjugate mAb A45-B/B3-alkaline phosphatase
to cytoskeletal CKs (45 min), and formation of an insoluble red
reaction product at the site of binding of the specific conjugate
(15 min) using the DAKO-APAAP detection kit (DakoCytoma-
tion, Glostrup, Denmark) according to the manufacturer's
instructions. Subsequently, the cells were mounted with Kai-
ser's glycerol/gelatine (Merck, Darmstadt, Germany) in Tris-
ethylenediamine tetraacetic acid buffer (Sigma). A control anti-
body (conjugate of Fab fragment; Micromet) served as nega-
tive control. For each test a positive control slide with theAvailable online http://breast-cancer-research.com/content/11/4/R59
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breast carcinoma cell line MCF-7 (ATCC, Rockville, MD, USA)
was treated under the same conditions.
Evaluation of CK-positive cells
Microscopic evaluation of the slides was carried out using the
ACIS system (Chromavision, San Juan Capistrano, CA, USA)
at the Department of Gynecology and Obstetrics, Tübingen
and using the ARIOL system (Applied Imaging, Newcastle
upon Tyne, UK) at the Department of Gynecology and Obstet-
rics, Essen according to the ISHAGE evaluation criteria and
the DTC consensus [19,20]. These automated scanning
microscopes and image analysis systems consist of a slide
Table 1
Clinical data of patients
Total CTC-positive P value Total DTC-positive P value
Total 431 58 (13) 414 107 (24)
Tumor size
pT1 285 34 (12) 0.47 274 66 (24) 0.07
pT2 to pT4* 134 21 (16) 130 40 (31)
bilateral 10 2 (20) 9 0 (0)
Nodal status
Node-negative 286 32 (11) 0.04 273 71 (26) 0.92
Node-positive 142 26 (18) 137 35 (26)
Histology
Ductal 349 45 (13) 0.33 337 85 (25) 0.54
Lobular 65 12 (19) 60 16 (27)
Others 16 1 (6) 16 6 (38)
Grading
I 58 6 (10) 0.11 57 14 (25) 0.76
II 270 32 (12) 255 64 (25)
III 102 20 (20) 101 29 (29)
ER status
Negative 60 13 (22) 0.05 57 15 (26) 0.93
Positive 371 45 (12) 357 92 (26)
PR status
Negative 75 17 (23) 0.01 70 25 (36) 0.04
Positive 356 41 (12) 344 82 (24)
HER2
Negative 380 49 (13) 0.35 365 89 (24) 0.06
Positive 51 9 (18) 49 18 (37)
Bone marrow status
Positive 106 20 (19) 0.05
Negative 299 34 (11)
Immunhistochemical subtype
(ER-, PR-, HER2-) 26 8 (30) 0.01 23 7 (30) 0.62
(ER-, PR-, HER2+) 11 0 11 4 (36)
(ER+ and/or PR+) 394 50 (13) 380 96 (25)
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.Breast Cancer Research    Vol 11 No 4    Fehm et al.
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loader, camera, computer and software for the detection and
classification of cells of interest based on particular color,
intensity, size, pattern, and shape. All slides were evaluated at
both the Tübingen (TF) and Essen (SK-B) centers. In case
nonconcordant results were obtained, slides were evaluated
by a third investigator (EFS) to obtain consensus.
Sampling of blood
Two samples of 5 ml ethylenediamine tetraacetic acid blood
were collected for isolation of CTCs before the application of
therapeutic substances with an S-Monovette® (Sarstedt AG &
Co, Nümbrecht, Germany) and were stored at 4°C until further
examination. The samples were processed immediately or not
later than 4 hours after blood withdrawal. An additional serum
sample was collected to determine serum tumor markers.
Tumor cell enrichment/selection
Blood samples were taken from 431 patients and were ana-
lyzed for CTCs with the AdnaTest BreastCancer™ (AdnaGen
AG), which enables the immunomagnetic enrichment of tumor
cells via epithelial and tumor-associated antigens. Establish-
ment and validation of the AdnaTest BreastCancer™ assay
has been described in detail elsewhere [21-23,35]. The lower
detection limit of this assay is based on spiking experiments
two cells per 5 ml [35]. Examination of blood samples of
healthy donors (n = 106) yielded a specificity of 95% [35].
In brief, blood samples were incubated with a ready-to-use
antibody mixture (against GA 73.3 and MUC1) commercial-
ized as AdnaTest BreastCancerSelect (AdnaGen AG, Lan-
genhagen, Germany) according to the manufacturer's
instructions. The labeled cells were extracted by a magnetic
particle concentrator. Subsequently, mRNA isolation from
lysed, enriched cells was performed according to the manu-
facturer's instructions with the Dynabeads mRNA DIRECT™
Micro Kit (Dynal Biotech GmbH, Hamburg, Germany) that is
included in the AdnaTest BreastCancerDetect (AdnaGen
AG). Reverse transcription resulted in cDNA, which was the
template for tumor cell detection and characterization by mul-
tiplex RT-PCR. Sensiscript® Reverse Transcriptase (QIAGEN
GmbH, Hilden, Germany) was used for the reverse transcrip-
tion because of its high sensitivity (recommended for < 50 ng
RNA) in combination with oligo(dT)-coupled Dynabeads of the
mRNA DIRECT™ Micro Kit (Dynal Biotech GmbH, Hamburg,
Germany) according to the manufacturer's instructions [35].
Tumor cell detection
The Adnatest BreastCancerDetect was used for the detection
of breast cancer-associated gene expression in immunomag-
netically enriched tumor cells by reverse transcription and
PCR. The analysis of tumor-associated mRNA isolated from
CTCs was performed in a multiplex PCR for the three tumor-
associated transcripts HER2, MUC1 and GA 733-2 followed
by storage of the samples at 4°C.
The primer sets for the ER and PR receptor were provided by
Adnagen AG. These reagents detected ER and PR on CTCs
after the preparation of the cDNA and according to the manu-
facturer's instructions of the AdnaTest BreastCancerDetect.
PCR was performed with the HotStarTaq Master Mix (QIA-
GEN GmbH). Actin was used as the internal PCR positive
control. The thermal profile used for the nested RT-PCR was
as follows. After a 15-minute denaturation at 95°C, 37 cycles
of PCR were carried out by denaturation at 94°C for 30 sec-
onds, annealing/extension at 60°C for 30 seconds and elon-
gation for 30 seconds at 72°C. Termination of the reaction
was subsequently carried out at 72°C for 5 minutes followed
by storage of the samples at 4°C.
The primers generate fragments of the following sizes: GA
733-2, 395 bp; MUC1, 293 bp; HER2, 270 bp; PR, 270 bp;
ER, 305 bp; and actin, 114 bp. Visualization of the PCR frag-
ments was carried out with a 2100 Bioanalyzer using the DNA
1000 LabChips (Agilent Technologies, Santa Clara, CA, USA)
and the Expert Software Package (Agilent Technologies; ver-
sion B.02.03.SI307).
Evaluation of data established for circulating tumor cells
The test is considered positive if a PCR fragment of at least
one tumor-associated transcript (MUC-1, GA 733-2 or HER2)
is clearly detected. Using the software package for evaluation
of the data on the Agilent 2100 Bioanalyzer, peaks with a con-
centration > 0.15 ng/μl are positive for the transcripts GA
733-2, MUC1 and HER2. Peaks with a concentration > 0.60
ng/μl are positive for the ER transcript. The PR expression is
considered positive when the transcript is detected without
applying any cutoff value.
Immunohistochemical analysis of the primary tumor
For each of the 431 patients, the tumor type, TNM staging and
grading were assessed according to the World Health Organ-
ization Classification of tumors of the breast [36] and the sixth
edition of the TNM Classification System [37].
The ER status and PR status were determined by immunohis-
tochemistry. Sections of 5 μm thickness were cut and
mounted on SuperFrost® Plus slides (Menzel, Braunschweig,
Germany). Following individually optimized heat-based
antigen retrieval for each antibody, each glass slide was immu-
nostained with commercially available antibodies. The follow-
ing antibodies were used: anti-ER (clone SP1; DCS,
Hamburg, Germany), dilution 1:300, antigen retrieval for 30
minutes in a 95°C waterbath, citrate buffer, pH 6.0; and anti-
PR (clone 16; DCS), dilution 1:200, antigen retrieval for 30
minutes in a 95°C waterbath, citrate buffer, pH 6.0.
Automated immunohistochemistry was performed using the
Dako Autostainer Plus System (DakoCytomation, Carpinteria,
CA, USA) with the anti-mouse IgG EnVision Plus detection kit
(DakoCytomation) for secondary and tertiary immunoreac-Available online http://breast-cancer-research.com/content/11/4/R59
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tions. Reaction products were developed with diaminobenzi-
dine, according to general protocols. Positive and negative
control sections were included in each run, which showed
appropriate results.
The DAKO score for the expression of HER2 was determined
with the HercepTest, and fluorescence in situ hybridization
analysis in cases of 2+ staining as determined with the Her-
cepTest was performed as described elsewhere [38].
Statistical analysis
The chi-squared test or Fisher's exact test was used to evalu-
ate the relationship between DTCs and CTCs and clinico-
pathological factors. Statistical analysis was performed with
SPSS software (version 11.5; SPSS Inc., Chicago, IL, USA).
P < 0.05 was considered statistically significant.
Results
Patients' characteristics
A total of 431 patients were included in the study: 285 out of
431 (66%) patients had T1 tumors, and 286 out of 431 (66%)
patients were node-negative. The expression of therapeutic
relevant markers in primary tumors was available from all 431
patients. ER and PR positivity was observed in 86% (371/
431) and 83% (356/431) of the tumors, respectively. HER2
was overexpressed in 12% (51/431) of the cases. Classifying
tumors into subtypes based on their ER, PR and HER2 expres-
sion, 91% of the tumors were ER-positive and/or PR-positive,
6% were triple-negative (ER-negative/PR-negative/HER2-
negative) and 11 tumors only expressed HER2 (ER-negative/
PR-negative/HER2-positive). Clinical data are presented in
detail in Table 1.
Incidence of circulating tumor cells in blood
A blood sample was regarded CTC-positive if at least one of
the three markers GA 733-2, MUC1 or HER2 was expressed.
The detection rate for CTCs was 13% (58/431 patients) with
the expression rates of 55% for EpCAM (32/58 patients),
53% for MUC1 (31/58 patients) and 38% for HER2 (22/58
patients) (Table 2). The presence of CTCs significantly corre-
lated with positive nodal status (P = 0.04), negative ER (P =
0.05) and negative PR (P = 0.01), respectively. The highest
CTC positivity rate was obtained in triple-negative patients fol-
lowed by those with ER-positive and/or PR-positive tumors
(30% vs. 13%, P = 0.01). No CTCs could be detected in the
HER2-positive subtype group (Table 1).
Correlation of disseminated and circulating tumor cells 
with established prognostic markers
The BM status of DTCs was available in 414 patients. DTCs
were found in 107 out of 414 (24%) patients. No correlation
could be observed between positive BM status and the estab-
lished prognostic markers except for the PR status of the pri-
mary tumor (P = 0.04; Table 1). The CTC status was weakly
associated with the presence of DTCs in BM (P = 0.05; Table
1). The positivity rate was 19% in patients with positive BM
status compared with 11% in those with negative BM status.
Expression profiling of circulating tumor cells and 
corresponding tumors
The expression profile of CTCs included ER, PR, and HER2.
The expression rates were 38% for HER2 (22/58 patients),
25% for ER (12/48 patients) and 4% for PR (2/48 patients).
In 10 patients, the ER and PR expression could not be deter-
mined in CTCs due to the small sample volume. Regarding the
immunohistochemical subtype, 50% of the CTCs (24/48
patients) were triple-negative and 21% (10/48 patients) were
only HER2-positive. The remaining 29% of CTCs (14/48
patients) were ER-positive and/or PR-positive with positive or
negative HER2 status. Comparing the expression profile
between CTCs and the primary tumor, ER positivity of the pri-
mary tumor was demonstrated in 45 out of 58 (78%) of these
patients, PR positivity in 41 out of 58 (71%) patients and
HER2 positivity in 9 out of 58 (16%) patients. The concord-
ance rate between ER, PR and HER2 status of CTCs and the
primary tumor was 29%, 25% and 53%, respectively (Table
2). Interestingly, CTCs were triple-negative in 50% (24/48) of
all cases whereas only 15% (7/48) of the primary tumors were
negative for ER, PR and HER2 (see Figure 1).
Table 2
Expression profile of circulating tumor cells in breast cancer patients compared with the primary tumor
Circulating tumor cells Primary tumor (n = 58) Concordance (%)
nn % n %
E R - p o s i t i v e 4 8 1 22 54 57 82 9
PR-positive 48 2 2 41 71 25
H E R 2 - p o s i t i v e 5 8 2 23 89 1 65 3
Muc-1-positive 58 31 53 - - -
GA 73.3-positive 58 32 55 - - -
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.Breast Cancer Research    Vol 11 No 4    Fehm et al.
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Discussion
Recent publications have indicated that the presence of CTCs
and DTCs in peripheral blood and BM, respectively, does not
provide congruent results and that there is a more complex
relationship between the primary tumor and DTCs on the phe-
notype level as well on the genomic level. We demonstrate
here, in a large patient group: a weak correlation between the
presence of CTCs in peripheral blood and the presence of
DTCs in BM; that CTCs are more closely related to the biology
of the primary tumor than DTCs; that the majority of CTCs are
triple-negative, regardless of the antigen expression of the pri-
mary tumor; and, most interestingly, that CTCs mostly derive
from triple-negative tumors.
Incidence of circulating tumor cells in primary breast 
cancer
Using a multiplex RT-PCR approach, our positivity rate was
13% in primary breast cancer. Detection rates reported by
other researchers using different approaches range from 9%
to 50% depending on the clinical stages included [11-21,27-
30]. There is still currently an ongoing debate whether the (RT-
)PCR-based approach (for example, the AdnaTestBreastCan-
cer™) or the antibody-based approach (for example, the Cell-
Search™ system) is superior in a clinical setting to monitor
therapy response and to predict prognosis.
False positive results can be obtained using both the molecu-
lar approach and the antibody-based assay since only epithe-
lial but not unique breast cancer specific markers are available
for identification of breast cancer tumor cells. These markers
can also be expressed in contaminating stimulated leukocytes
[19,39]. The antibody-based approach allows a morphological
assessment to confirm malignancy based on cytomorphologi-
cal criteria [33,34]. In contrast, the RT-PCR approach seems
to be more sensitive and allows easy multiple marker testing
[39,40].
Until now, only few studies have compared both techniques
[40,41]. Trials have been initiated (for example, the DETECT
Study) to determine the CTC status using both the antibody-
based assay and the molecular-based approach to elucidate
which assay provides more valid data in predicting therapy
response and prognosis [26].
Correlation between circulating tumor cells in peripheral 
blood and disseminated tumor cells in bone marrow
Some research groups compared the relationship between
the presence of DTCs in BM and CTCs in blood [15-18]. In
general, correlation between DTCs and CTCs is low. It has
been demonstrated that, in contrast to the detection of DTCs
in BM of patients with early disease, detection of CTCs
appears to be less sensitive and less prognostic [16,17]. Fur-
thermore, there is growing evidence that the prognosis of
women with primary breast cancer depends on DTCs rather
than CTCs [15,16,42]. In our study, there was a weak correla-
tion between the presence of CTCs in peripheral blood and
the presence of DTCs in BM, and the presence of CTCs was
more closely related to the biology of the primary tumor than
DTCs. Only the clinical follow-up data of the patients, how-
ever, will elucidate the prognostic significance of either CTCs
or DTCs, or both.
Expression profile of circulating tumor cells compared 
with the primary tumor
The aim of adjuvant treatment is to eliminate minimal residual
disease reflected by CTCs and DTCs. The predictive markers
ER, PR and HER2, however, are determined in the primary
tumor to determine whether HER2 targeted therapy and endo-
crine therapy will be effective. One of the main objectives of
the present paper was therefore to determine the concord-
ance of the predictive markers ER, PR and HER2 between
CTCs and corresponding primary tumors.
On the phenotype level, the expression of HER2 on DTCs or
CTCs of patients with primary breast cancer has been pub-
lished by different groups – who independently indicated that
HER2 expression on both DTCs and CTCs differed from
HER2 expression in the primary tumor and that the expression
of HER2 on DTCs and CTCs was correlated with poor prog-
nosis [32,43-46]. These observations might have clinical rele-
vance when selecting patients for HER2 targeted therapy.
Patients with HER2-negative tumors but HER2-positive CTCs
might also benefit from HER2 targeted therapy. In a metastatic
setting, Meng and colleagues have already shown that meta-
static patients who were regarded as HER2-negative on the
basis of HER2 expression of their primary tumor had circulat-
ing HER2-positive cells and responded to trastuzumab [47].
Figure 1
Expression of circulating tumor cells and corresponding primary tumors  based on receptor status Expression of circulating tumor cells and corresponding primary tumors 
based on receptor status. Expression profile of circulating tumor cells 
(CTCs) and corresponding primary tumors (PTs) in breast cancer 
patients after stratifying into three different groups based on estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2(HER2) status: ER-positive and/or PR-positive, 
triple-negative (ER-negative/PR-negative/HER2-negative), and HER2-
positive (but ER-negative/PR-negative).Available online http://breast-cancer-research.com/content/11/4/R59
Page 7 of 9
(page number not for citation purposes)
Similarly, the hormonal status of DTCs and CTCs could be
completely different from that of the primary tumor, which on
the one hand (tumor-negative, DTC/CTC-positive) could
increase the number of patients eligible for endocrine therapy
and on the other (tumor-positive, DTC/CTC-negative) could
explain why endocrine therapy fails in a subset of hormone
receptor-positive patients. Ditsch and colleagues, in an obser-
vational study looking at 17 primary tumors and their corre-
sponding DTCs, found that only 2 out of 11 patients (18%)
with ERα-positive primary tumors had ERα-positive DTCs
[48]. We recently demonstrated in a cohort of 254 patients
with primary breast cancer that the primary tumor and DTCs in
BM displayed a concordant ERα status in only 28% of cases
[31].
Studies comparing the expression of HER2 as well as ER/PR
expression of the primary tumor with CTCs have rarely been
published. As already published in our study on metastatic
breast cancer, we here show that CTCs were more likely to be
ER-negative and PR-negative compared with the primary
tumor. In contrast, CTCs were HER2-positive in 38% of the
patients whereas only 16% of the corresponding primary
tumors expressed HER2 [49,50]. The results are therefore
similar to the data derived from the DTC studies.
These phenotypical changes or discrepancies between the
primary tumor, DTCs and CTCs are not confined to hormonal
receptors and HER2 alone, since other studies looking at
markers such as MHC III, Ki-76 and EGF-R have reported sim-
ilar discrepancies [51-53]. In summary, all published data sug-
gest that CTCs and DTCs may represent a unique and
heterogeneous cell population.
Looking at a large patient group, our data confirm these previ-
ous findings of smaller studies, indicating that reliance on the
phenotype of the primary tumor can be misleading since HER2
as well as the hormonal receptors were differently expressed
on CTCs as compared with the primary tumor. These results
have major implications for selecting adjuvant treatment. Since
the expression profile of predictive markers of DTCs and
CTCs, the target of adjuvant treatment, differs from the corre-
sponding primary tumor, the next step is to design a clinical
trial stratifying adjuvant treatment based on the expression
profile of CTCs or DTCs versus the primary tumor to deter-
mine whether patients will derive more benefit from therapy
selected based on the expression profile of minimal residual
disease.
Characterization of circulating tumor cells and 
corresponding shedding primary tumors
On stratifying our patients into three different groups accord-
ing to the tumor subtype classifications, the majority of
patients had ER/PR-positive tumors. Only 6% of the patients
were triple-negative, which is low compared with reported inci-
dences of 15 to 30% [54]. The low incidence may be due to
the fact that nearly all patients included in this study were Cau-
casian and had a high socioeconomic status (for example, not
obese) [54,55].
CTCs were mostly found in patients with triple-negative
tumors. In addition, most of the CTCs were triple-negative
regardless of the subtype of the primary tumor. Different
hypotheses need to be discussed with regard to our findings.
One possible explanation is the clonal heterogeneity of the pri-
mary tumor, allowing only a certain subpopulation to dissemi-
nate. On first view, it seems that ER-negative, PR-negative and
HER2-negative cells could more probably disseminate, corre-
sponding to the worse prognosis of predominantly ERα-nega-
tive tumors and – inversely – to the demonstrated decreased
invasiveness and metastatic potential of ERα-expressing
breast cancer cells [56,57].
One currently discussed hypothesis is the theory that some
DTCs or CTCs, the presumed precursor cells of systemic met-
astatic disease, are in fact cancer stem cells. As recently pub-
lished, this theory states that tumor growth and formation of
secondary tumors can be traced to a small subpopulation of
tumor cells, so-called cancer stem cells [58,59]. At least one
study has confirmed a putative stem cell phenotype in DTCs
[60], and another study has shown that the majority of early
DTCs detected in the BM of breast cancer patients with a
CD44+/CD24- phenotype correlated with a higher prevalence
of bone metastases [61]. As breast cancer stem cells have
been shown to be generally triple-negative, triple-negative
CTCs are in concordance with the cancer stem cell theory
[62,63].
Conclusions
Two major conclusions can be drawn from these results. First,
CTCs and DTCs have different meanings due to the low con-
cordance. To determine the difference in predicting prognosis,
clinical follow-up is needed. Second, CTCs have a different
expression profile compared with the primary tumor. The
impact on adjuvant treatment can only be answered in clinical
trials randomizing patients according to the expression profile
based on CTCs or DTCs.
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